Vimarsana
Biggest News Aggregation in the World

Page 2 - Ascending Dose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ascending Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ascending Dose Today - Breaking & Trending Today

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference - Vimarsana News

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

MALVERN, Pa., Sept. 29, 2023 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today...

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones - Vimarsana News

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

06.03.2023 - Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for Autoimmune Indications, Advances into Multi-Ascending Dose Trial Well-capitalized with Operating Runway ...

Annexon Highlights Strategic Focus to Advance Four Flagship - Vimarsana News

Annexon Highlights Strategic Focus to Advance Four Flagship

Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates - Vimarsana News

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS stock surges after Phase 1 data for kidney disease candidate (NASDAQ:RGLS) - Vimarsana News

RGLS stock surges after Phase 1 data for kidney disease candidate (NASDAQ:RGLS)

The shares of clinical-stage biotech Regulus Therapeutics Inc